JP7479362B2 - コルチコステロイドの粘膜付着性医薬組成物 - Google Patents

コルチコステロイドの粘膜付着性医薬組成物 Download PDF

Info

Publication number
JP7479362B2
JP7479362B2 JP2021521814A JP2021521814A JP7479362B2 JP 7479362 B2 JP7479362 B2 JP 7479362B2 JP 2021521814 A JP2021521814 A JP 2021521814A JP 2021521814 A JP2021521814 A JP 2021521814A JP 7479362 B2 JP7479362 B2 JP 7479362B2
Authority
JP
Japan
Prior art keywords
composition
amount
minutes
hours
corticosteroid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021521814A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022505535A5 (https=
JP2022505535A (ja
Inventor
アルノー グルニエ
ダリオ カラーラ
Original Assignee
フェリング ベスローテン フェンノートシャップ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=68296606&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7479362(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by フェリング ベスローテン フェンノートシャップ filed Critical フェリング ベスローテン フェンノートシャップ
Publication of JP2022505535A publication Critical patent/JP2022505535A/ja
Publication of JP2022505535A5 publication Critical patent/JP2022505535A5/ja
Application granted granted Critical
Publication of JP7479362B2 publication Critical patent/JP7479362B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2021521814A 2018-10-24 2019-10-23 コルチコステロイドの粘膜付着性医薬組成物 Active JP7479362B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862749878P 2018-10-24 2018-10-24
US62/749,878 2018-10-24
EP19150077 2019-01-02
EP19150077.6 2019-01-02
PCT/IB2019/059079 WO2020084530A1 (en) 2018-10-24 2019-10-23 Mucoadhesive pharmaceutical compositions of corticosteroids

Publications (3)

Publication Number Publication Date
JP2022505535A JP2022505535A (ja) 2022-01-14
JP2022505535A5 JP2022505535A5 (https=) 2022-10-31
JP7479362B2 true JP7479362B2 (ja) 2024-05-08

Family

ID=68296606

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021521814A Active JP7479362B2 (ja) 2018-10-24 2019-10-23 コルチコステロイドの粘膜付着性医薬組成物

Country Status (16)

Country Link
US (1) US12539306B2 (https=)
EP (3) EP4233872B1 (https=)
JP (1) JP7479362B2 (https=)
KR (1) KR102862769B1 (https=)
CN (1) CN113271979A (https=)
AU (1) AU2019365253B2 (https=)
BR (1) BR112021007140A2 (https=)
CA (1) CA3116649A1 (https=)
CL (1) CL2021001046A1 (https=)
CO (1) CO2021005913A2 (https=)
DK (1) DK3870226T3 (https=)
ES (2) ES2956849T3 (https=)
FI (2) FI3870226T3 (https=)
MX (1) MX2021004537A (https=)
PL (2) PL3870226T3 (https=)
WO (1) WO2020084530A1 (https=)

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003128586A (ja) 2001-09-18 2003-05-08 Johnson & Johnson Consumer Co Inc 物理的に安定で噴霧可能なゲル組成物
JP2005533047A (ja) 2001-06-07 2005-11-04 チョウ・コンサルティング・インコーポレイテッド アフタ潰瘍および単純ヘルペス病変の予防および処置のための組成物および方法
US20070111978A1 (en) 2005-11-12 2007-05-17 Ranjan Dohil Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
JP2007522077A (ja) 2003-08-21 2007-08-09 アクセス ファーマシューティカルズ， インコーポレイテッド 粘膜の疾患および障害の予防および処置のための液体製剤
JP2008539222A (ja) 2005-04-26 2008-11-13 フォーミックス エルティーディー． ステロイドキット及び起泡性組成物、並びにその使用
JP2011503113A (ja) 2007-11-13 2011-01-27 メリテイジ ファーマ，インク． 胃腸炎の治療用組成物
JP2011529854A (ja) 2008-05-14 2011-12-15 オトノミ―，インク． 制御放出型コルチコステロイド組成物、および耳の疾患を処置する方法
US20120164080A1 (en) 2010-06-24 2012-06-28 Meritage Pharma, Inc. Methods of treatment for esophageal inflammation
JP2012528889A (ja) 2009-06-05 2012-11-15 アーシエックス セラピューティックス， インコーポレイテッド フルチカゾンの眼科処方物および使用方法
JP2015536995A (ja) 2012-11-09 2015-12-24 サイドース・エルエルシー 潰瘍性大腸炎の治療のための長期安定性を有する浣腸剤組成物
JP2017514843A (ja) 2014-05-01 2017-06-08 インテグラル バイオシステムズ エルエルシー 眼疾患の治療のための膜付着性の自己組織化システム
JP2018515511A (ja) 2015-05-04 2018-06-14 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 結腸に治療剤を送達するための組成物及び方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5458879A (en) 1994-03-03 1995-10-17 The Procter & Gamble Company Oral vehicle compositions
US5554380A (en) 1994-08-04 1996-09-10 Kv Pharmaceutical Company Bioadhesive pharmaceutical delivery system
US6319513B1 (en) 1998-08-24 2001-11-20 The Procter & Gamble Company Oral liquid mucoadhesive compounds
US20010016577A1 (en) 1998-08-24 2001-08-23 Douglas Joseph Dobrozsi Oral mucoadhesive compositions containing gastrointestinal actives
WO2001028515A1 (en) * 1999-10-22 2001-04-26 Líf-Hlaup ehf. Bio-Gels Pharmaceuticals Inc. Pharmaceutical composition for treatment of mucosal epithelial ulceration and/or erosion
PT1997478E (pt) 2001-02-15 2013-12-10 Access Pharma Inc Formulações líquidas para a prevenção e para o tratamento de doenças e distúrbios das mucosas
US7544348B2 (en) 2001-02-15 2009-06-09 Access Pharmaceuticals, Inc. Liquid formulations for the prevention and treatment of mucosal diseases and disorders
US8030003B2 (en) 2004-12-07 2011-10-04 Children's Hospital Medical Center Diagnosis of eosinophilic esophagitis based on presence of an elevated level of eotaxin-3
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8679545B2 (en) 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
CL2007002214A1 (es) 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
US20100216754A1 (en) * 2007-11-13 2010-08-26 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
CN101969956B (zh) * 2007-11-13 2014-03-05 梅里蒂奇制药公司 皮质类固醇组合物
US8865692B2 (en) 2007-11-13 2014-10-21 Meritage Pharma, Inc Compositions for the treatment of gastrointestinal inflammation
US20090264392A1 (en) 2008-04-21 2009-10-22 Meritage Pharma, Inc. Treating eosinophilic esophagitis
CA2723215A1 (en) 2008-05-01 2009-11-05 Revalesio Corporation Compositions and methods for treating digestive disorders
ES2358158T3 (es) 2008-07-21 2011-05-06 Dr. Falk Pharma Gmbh Formulación farmacéutica para el tratamiento del tracto digestivo superior.
HUE051538T2 (hu) 2008-08-20 2021-03-01 Univ California Kortikoszteroidok a gyomor-bél traktus gyulladásos betegségeinek kezelésére
AU2009322556A1 (en) 2008-12-01 2011-07-21 Children's Hospital Medical Center Methods of determining efficacy of glucocorticoid treatment of eosinophilic esophagitis
WO2010144865A2 (en) 2009-06-12 2010-12-16 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
JP5833007B2 (ja) 2009-08-31 2015-12-16 ドクター・レディーズ・ラボラトリーズ・リミテッド ステロイドを含む局所製剤
MX364947B (es) 2009-10-01 2019-05-15 Adare Pharmaceuticals Inc Composiciones de corticosteroides administradas oralmente.
CN103974706A (zh) 2011-10-06 2014-08-06 N·V·努特里奇亚 嗜酸细胞性食管炎的治疗
EP2938327B1 (en) 2012-12-26 2017-12-06 Otic Pharma Ltd. Foamable otic pharmaceutical compositions
WO2014155397A1 (en) 2013-03-29 2014-10-02 Italchimici S.P.A. Oral suspension for treating eosinophilic esophagitis
WO2015034678A2 (en) 2013-09-06 2015-03-12 Aptalis Pharmatech, Inc. Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
PT2886108T (pt) 2013-12-23 2019-04-01 Dr Falk Pharma Gmbh Formulação farmacêutica otimizada para o tratamento de alterações inflamatórias do esófago
US20160184431A1 (en) 2014-03-11 2016-06-30 Promius Pharma Llc Topical compositions comprising a corticosteroid
US11623008B2 (en) 2014-08-20 2023-04-11 Professional Compounding Centers Of America Excipient compositions for mucoadhesive pharmaceutical compositions including a synergistic combination of amylopectin, pullulan, hyaluronic acid, and xyloglucan
DE102014119576A1 (de) * 2014-12-23 2016-06-23 Ernst-Moritz-Arndt-Universität Greifswald Pharmazeutische Arzneimittelform zur Applikation auf Schleimhäuten
BR102018008324A2 (pt) 2018-04-25 2019-11-05 Laboratorios Ferring Ltda composição farmacêutica de uso tópico e processo de fabricação de composição farmacêutica de uso tópico

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005533047A (ja) 2001-06-07 2005-11-04 チョウ・コンサルティング・インコーポレイテッド アフタ潰瘍および単純ヘルペス病変の予防および処置のための組成物および方法
JP2003128586A (ja) 2001-09-18 2003-05-08 Johnson & Johnson Consumer Co Inc 物理的に安定で噴霧可能なゲル組成物
JP2007522077A (ja) 2003-08-21 2007-08-09 アクセス ファーマシューティカルズ， インコーポレイテッド 粘膜の疾患および障害の予防および処置のための液体製剤
JP2008539222A (ja) 2005-04-26 2008-11-13 フォーミックス エルティーディー． ステロイドキット及び起泡性組成物、並びにその使用
US20070111978A1 (en) 2005-11-12 2007-05-17 Ranjan Dohil Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
JP2011503073A (ja) 2007-11-13 2011-01-27 メリテイジ ファーマ，インク． コルチコステロイド組成物
JP2011503113A (ja) 2007-11-13 2011-01-27 メリテイジ ファーマ，インク． 胃腸炎の治療用組成物
JP2011529854A (ja) 2008-05-14 2011-12-15 オトノミ―，インク． 制御放出型コルチコステロイド組成物、および耳の疾患を処置する方法
JP2012528889A (ja) 2009-06-05 2012-11-15 アーシエックス セラピューティックス， インコーポレイテッド フルチカゾンの眼科処方物および使用方法
US20120164080A1 (en) 2010-06-24 2012-06-28 Meritage Pharma, Inc. Methods of treatment for esophageal inflammation
JP2015536995A (ja) 2012-11-09 2015-12-24 サイドース・エルエルシー 潰瘍性大腸炎の治療のための長期安定性を有する浣腸剤組成物
JP2017514843A (ja) 2014-05-01 2017-06-08 インテグラル バイオシステムズ エルエルシー 眼疾患の治療のための膜付着性の自己組織化システム
JP2018515511A (ja) 2015-05-04 2018-06-14 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 結腸に治療剤を送達するための組成物及び方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPGN，2017年，64(2)，pp.218-224
Pharm Technol Hosp Pharm，2018年，3(2)，pp.71-77
Pharm Technol Hosp Pharm，2018年，3(2)，pp.91-99

Also Published As

Publication number Publication date
CL2021001046A1 (es) 2022-01-07
JP2022505535A (ja) 2022-01-14
MX2021004537A (es) 2021-06-15
AU2019365253A1 (en) 2021-05-27
FI3870226T3 (fi) 2023-09-15
ES2956849T3 (es) 2023-12-29
FI4233872T3 (fi) 2025-10-02
DK3870226T3 (da) 2023-09-18
CO2021005913A2 (es) 2021-05-20
ES3043383T3 (en) 2025-11-25
PL3870226T3 (pl) 2023-12-27
EP3870226B1 (en) 2023-06-28
US12539306B2 (en) 2026-02-03
CN113271979A (zh) 2021-08-17
CA3116649A1 (en) 2020-04-30
WO2020084530A1 (en) 2020-04-30
EP4233872A3 (en) 2023-10-11
EP4233872A2 (en) 2023-08-30
EP3870226A1 (en) 2021-09-01
EP4233872B1 (en) 2025-07-02
US20210379081A1 (en) 2021-12-09
EP4603097A3 (en) 2025-10-22
AU2019365253B2 (en) 2025-02-20
KR20210088547A (ko) 2021-07-14
EP4603097A2 (en) 2025-08-20
KR102862769B1 (ko) 2025-09-19
BR112021007140A2 (pt) 2021-07-20
PL4233872T3 (pl) 2025-11-24

Similar Documents

Publication Publication Date Title
JP6744891B2 (ja) コルチコステロイド組成物
US10272037B2 (en) Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
US20220323463A1 (en) Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
EP2328553B1 (en) Corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
TWI393576B (zh) 供雄激素透黏膜投予用的呈膜形式之黏膜黏著性藥學組成物
JP7479362B2 (ja) コルチコステロイドの粘膜付着性医薬組成物
RU2805936C1 (ru) Мукоадгезивные фармацевтические композиции на основе кортикостероидов
WO2018193423A1 (en) Oral pharmaceutical compositions of corticosteroids
HK40096558A (en) Mucoadhesive pharmaceutical compositions of corticosteroids
HK40096558B (en) Mucoadhesive pharmaceutical compositions of corticosteroids
HK40058424A (en) Mucoadhesive pharmaceutical compositions of corticosteroids
HK40058424B (en) Mucoadhesive pharmaceutical compositions of corticosteroids

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221021

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221021

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230906

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230911

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231128

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231211

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240228

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240325

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240423

R150 Certificate of patent or registration of utility model

Ref document number: 7479362

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150